OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX) in a report issued on Tuesday. The brokerage issued a sell rating on the stock.

Separately, Needham & Company LLC reaffirmed a buy rating and set a $4.25 target price on shares of OncoCyte in a report on Friday, August 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of Hold and a consensus price target of $4.06.

OncoCyte Stock Performance

NASDAQ:OCX opened at $3.19 on Tuesday. The company has a fifty day moving average of $3.12 and a two-hundred day moving average of $2.93. OncoCyte has a fifty-two week low of $2.08 and a fifty-two week high of $4.34.

OncoCyte (NASDAQ:OCX) last announced its earnings results on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. The firm had revenue of $0.10 million for the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%. As a group, sell-side analysts anticipate that OncoCyte will post -2.58 earnings per share for the current year.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.